The Role of Immunotherapy in Early-Stage NSCLC

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

The SKYSCRAPER-03 trial revealed that tiragolumab plus atezolizumab failed to improve progression-free survival compared with durvalumab in NSCLC.

Jacob Sands, MD

August 4th 2025

Local Consolidative Therapy Plus Osimertinib Yields PFS Benefit in Metastatic EGFR-Mutant NSCLC

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.

Kristi Rosa

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

Sevabertinib Monotherapy Elicits Durable Responses in HER2-Mutant NSCLC

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Sevabertinib is also being evaluated as a first-line therapy for patients with locally advanced or metastatic NSCLC with HER2 mutations in the ongoing phase 3 SOHO-02 trial (NCT06452277).

Tim Cortese

Zongertinib Maintains Efficacy Benefit in First-line HER2-Mutated NSCLC

Sevabertinib monotherapy was deemed tolerable across various cohorts of patients who were pretreated and treatment-naïve with HER2-mutant advanced NSCLC.

Ariana Pelosci

Tiragolumab/Atezolizumab Does Not Meet PFS End Point in NSCLC

Results from the Beamion LUNG-1 study showed that first-line zongertinib yielded continued benefit for patients with HER2-mutated NSCLC.

Related Content

Jason M. Broderick

October 18th 2025

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

The SKYSCRAPER-03 trial revealed that tiragolumab plus atezolizumab failed to improve progression-free survival compared with durvalumab in NSCLC.

Jacob Sands, MD

August 4th 2025

Local Consolidative Therapy Plus Osimertinib Yields PFS Benefit in Metastatic EGFR-Mutant NSCLC

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Kristi Rosa

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

Sevabertinib Monotherapy Elicits Durable Responses in HER2-Mutant NSCLC

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Tim Cortese

Zongertinib Maintains Efficacy Benefit in First-line HER2-Mutated NSCLC

Sevabertinib monotherapy was deemed tolerable across various cohorts of patients who were pretreated and treatment-naïve with HER2-mutant advanced NSCLC.

Ariana Pelosci